N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 200,000 shares at $25.43 ($5.1M) on 2023-11-03, disclosed to the SEC on 2023-11-06.
Open-market sale of $5.1M CERE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.19 | 38,599 | $972K | 19.2% |
| 2 | $25.19 | 38,599 | $972K | 19.2% |
| 3 | $25.43 | 61,401 | $1.6M | 30.8% |
| 4 | $25.43 | 61,401 | $1.6M | 30.8% |
| Total | $25.34 avg | 200,000 | $5.1M | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |